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Chemokines are crucial autocrine and paracrine players in tumor development. In particular,
CXCL12, through its receptors CXCR4 and CXCR7, affects tumor progression by controlling
cancer cell survival, proliferation and migration, and, indirectly, via angiogenesis or
recruiting immune cells. Glioblastoma (GBM) is the most prevalent primary malignant brain
tumor in adults and despite current multimodal therapies it remains almost incurable. The
aggressive and recurrent phenotype of GBM is ascribed to high growth rate, invasiveness
to normal brain, marked angiogenesis, ability to escape the immune system and resistance
to standard of care therapies.Tumor molecular and cellular heterogeneity severely hinders
GBM therapeutic improvement. In particular, a subpopulation of chemo- and radio-therapy
resistant tumorigenic cancer stem–like cells (CSCs) is believed to be the main responsible
for tumor cell dissemination to the brain. GBM cells display heterogeneous expression
levels of CXCR4 and CXCR7 that are overexpressed in CSCs, representing a molecular
correlate for the invasive potential of GBM. The microenvironment contribution in GBM
development is increasingly emphasized. An interplay exists between CSCs, differentiated
GBMcells, and themicroenvironment, mainly through secreted chemokines (e.g., CXCL12)
causing recruitment of ﬁbroblasts, endothelial, mesenchymal and inﬂammatory cells to
the tumor, via speciﬁc receptors such as CXCR4. This review covers recent developments
on the role of CXCL12/CXCR4–CXCR7 networks in GBM progression and the potential
translational impact of their targeting. The biological and molecular understanding of the
heterogeneous GBM cell behavior, phenotype and signaling is still limited. Progress in
the identiﬁcation of chemokine-dependent mechanisms that affect GBM cell survival,
trafﬁcking and chemo-attractive functions, opens new perspectives for development of
more speciﬁc therapeutic approaches that include chemokine-based drugs.
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BACKGROUND
Chemokines (CKs) and their cognate receptors are constitutively
expressed in the central nervous system (CNS) where they con-
trol complex physiological functions. In particular, the pleiotropic
chemokine CXCL12 (formerly known as stromal-cell derived
factor-alpha, SDF1-α) and its receptorsCXCR4andCXCR7are key
regulators in CNS development, and are involved in neuromod-
ulation, neuroprotection, and control the interactions between
neurons, microglia and astrocytes in adult brain (Rostene et al.,
2007). Altered expression of CXCR4 and CXCL12 has also been
associated to CNS diseases, such as HIV encephalopathy, stroke
and multiple sclerosis, among others (Bajetto et al., 2001a; Ros-
tene et al., 2011). A role for CXCL12 modulation of CXCR4 and
CXCR7 was identiﬁed for most of the brain tumors including
gliomas, meningiomas and even pituitary adenomas that fre-
quently overexpress these receptors (Bajetto et al., 2007; Barbieri
et al., 2007; Duda et al., 2011). In this review we analyze the
role of CKs in glioblastoma (GBM) development, diffusion and
recurrence.
GBM is the most common and most malignant primary glial
tumor in adults, characterized by an invariably poor outcome
and limited therapeutic options (Dolecek et al., 2012). Standard
GBM management involves maximal surgical resection, followed
by radiotherapy with concomitant and adjuvant chemotherapy
with temozolomide, but in most cases GBM rapidly relapses.
Available treatments at relapse are largely ineffective and median
overall survival of GBM patients is about 15 months (Stupp et al.,
2005).
There is increasing evidence that tumor development, growth,
recurrence and resistance to chemo- and radio-therapy is related
to the presence of a cell subpopulation, named cancer stem cells
(CSCs), nowadays identiﬁed in different human hemopoietic and
solid cancers, includingGBM.EfﬁcientCSCeradication represents
the ineludible goal to prevent tumor relapse and thus a target for
all new anticancer approaches.
Beside its functional expression in embryonic pluripotent stem
cells, in adults CXCL12/CXCR4/R7 axis controls tissue-speciﬁc
stem cell proliferation (Singh et al., 2013). Similar functions
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have been hypothesized to occur also in CSCs. Thus the deﬁ-
nition of mechanisms and downstream mediators of CXCR4/R7
activation by CXCL12, in normal and malignant differentiated
cells, their progenitors, and in normal and CSCs, is highly
relevant for both cancer biology and perspective therapeutic
targeting.
CXCL12/CXCR4–CXCR7 SIGNALING
For many years CXCR4 has been considered the unique receptor
for CXCL12 and CXCL12 the sole ligand for CXCR4, a singu-
lar exception in the CK family that usually shows promiscuous
binding within multiple CKs and receptors. Later, CXCR7 (origi-
nally namedRDC1)was identiﬁed as second receptor for CXCL12,
showing 10-fold higher afﬁnity for CXCL12 than CXCR4 (Bal-
abanian et al., 2005), CXCR7 is a member of the atypical CK
receptor subgroup (ACKR),also includingDARC,D6, andCCRL1,
that do not activate G-proteins after correct binding with the
respective cognate ligand (Bachelerie et al., 2014). ACKR3 has
been proposed as the acronym for CXCR7 in this new nomencla-
ture system. Interestingly, CXCL12 shares CXCR7 binding with
another CK, CXCL11 (interferon-inducible T-cell α chemoat-
tractant, ITAC) that is also a ligand for CXCR3 (Singh et al.,
2013).
In the CXCR7 amino acid sequence, the highly conserved DRY-
LAIV domain, which controls G-protein binding and activation, is
DRYLSIT (Thelen andThelen, 2008). Typical CK responses,medi-
ated by G protein activity, such as intracellular Ca2+ mobilization
or modulation of adenylyl cyclase activity, are not generated after
CXCR7 binding. Due to the absence of Gi-coupling, CXCR7 was
initially proposed to be a decoy receptor, acting as a CXCL12
(and CXCL11) scavenger and able to promote ligand internal-
ization and degradation, to reduce CXCR4 activity (Graham et al.,
2012). However, the current vision is that this represents only
one of the possible mechanisms by which CXCR7 modulates cel-
lular functions (Sanchez-Martin et al., 2013). Emerging evidence
suggests that CXCR7 can activate intracellular signaling pathways,
and in particular it is able to elicit Akt, MAP kinase (MAPK),
and Janus kinase-signal transducer and activator of transcription
(JAK/STAT3) activation, either by direct modulation, through a
β-arrestin-dependent pathway (Singh et al., 2013) or after het-
erodimerization with CXCR4 (Wang et al., 2011; Hattermann and
Mentlein, 2013).
CXCL12 is a homeostatic CK, which controls hematopoietic
cell trafﬁcking and adhesion, in immune surveillance and devel-
opment, being constitutively expressed in different organs (e.g.,
bone marrow, heart, liver, lung, lymph nodes, liver, brain, kid-
ney, pituitary, among others). However, CXCL12 production has
been also correlated with pathological processes, such as inﬂam-
mation, heart failure, cell damage after organ irradiation or during
chemotherapy. In particular, CXCL12 secretion is particularly rel-
evant in hypoxic and pro-angiogenic environments within tumors
or during autoimmune diseases (Li and Ransohoff, 2009). CXCR4
is also a rather ubiquitous receptor, with a relevant role at the level
of endothelial mature and precursor cells and pericytes in healthy
conditions and in hypoxic or damaged vascular tissues, including
injured carotid arteries and atherosclerotic plaques (Petit et al.,
2007).
CXCL12 binding to CXCR4 triggers receptor homo- and het-
erodimerization, often, but not always, with CXCR7, depending
on the co-expression level of receptors (Levoye et al., 2009).
Ligand binding changes the CXCR4 three-dimensional confor-
mation favoring heterotrimeric G-proteins GDP/GTP exchange
and dissociation into α- and βγ-subunits, that, in turn, acti-
vate multiple transductional pathways (Bajetto et al., 2001a): αi
subunits inhibit cAMP formation via modulation of adeny-
lyl cyclase activity; the αq-subunit activates the phospholipase
C (PLC)-β, which hydrolyzes PIP2 (phosphatidylinositol 4,5-
bisphosphate) inducing the generation of diacylglycerol (DAG)
and inositol 1,4,5 trisphosphate (IP3) that controls the release
of intracellular Ca2+ from ER and the activation of protein
kinase C; Gαi subunits also induce the activation of the tran-
scription factor nuclear factor-κB (NF-κB), the Ca2+-dependent
tyrosine kinase PYK2, JAK/STAT, and the activation of the
phosphoinositide-3 kinase (PI3K)-Akt pathway, leading to cell
survival and proliferation. The βγ dimer, acting as a func-
tional subunit, is involved in Ras activation of ERK1/2 MAPK
cascade, leading to changes in gene expression and cell cycle
progression. CXCR4 also regulates cell survival by the G protein-
dependent activation of JNK and p38 MAPKs. Further, βγ
dimers interact with ion channels and activate PI3K, modulat-
ing CXCL12-dependent chemotaxis. CXCL12 also causes CXCR4
desensitization and uncoupling from G-proteins by GPCR kinase
(GRK)-dependent phosphorylation and subsequent interaction
of CXCR4 with β-arrestin that mediates internalization of the
receptor (Cheng et al., 2000) and targets desensitized CXCR4
to clathrin-coated pits for endocytosis. Moreover, interactions
between CXCR4 and β-arrestin also promote the activation
of downstream intracellular mediators including MAPKs (p38,
ERK1/2) and CXCL12-dependent chemotaxis (Sun et al., 2002).
Cell migration is directed by CXCR4 by the formation of a CK
gradient controlled by internalization of CXCL11 or CXCL12
bound to CXCR7, without the generation of intracellular sig-
naling (Luker et al., 2009). The formation of CXCR4–CXCR7
heterodimers, modulates CXCR4 signaling (Levoye et al., 2009)
and enhancesCXCL12-dependent intracellularCa2+mobilization
and ERK1/2 phosphorylation (Sierro et al., 2007), while chemo-
taxis induced by CXCL12 binding to CXCR4 is blocked by CXCR7
when expressed in the same cells (Decaillot et al., 2011). The
enhanced activity of CXCR4–CXCR7 heterodimers in recruit-
ing a β-arrestin complex, provides mechanistic insight into the
growth, survival, and migratory advantage provided by CXCR4
and CXCR7 co-expression in cancer cells. β-arrestin recruit-
ment to the CXCR4/CXCR7 complex enhances downstream,
β-arrestin-dependent cell signaling (ERK1/2, p38, SAPK/JNK),
which induces cell migration in response to CXCL12 (Cheng et al.,
2000; Sun et al., 2002; Singh et al., 2013). CXCR7 monomers
also promote ERK1/2 phosphorylation and nuclear transloca-
tion via G-protein-independent, β-arrestin-mediated signaling
(Rajagopal et al., 2010; Decaillot et al., 2011). CXCR7 mediates
CXCL12 signaling in cultured cortical astrocytes and Schwann
cells that co-express CXCR4. Stimulation of astrocytes with
CXCL12 activates ERK1/2, Akt but not p38 which was still
evident after gene silencing of CXCR4 but fully abrogated by
depletion of CXCR7. Conversely, in Schwann cells CXCL12
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triggers also p38 phosphorylation altogether with ERK1/2 and
Akt, but these effects require the activation of both receptors
(Odemis et al., 2010). A diagram of intracellular transduction
pathways related to CXCR4 and CXCR7 activation is depicted in
Figure 1.
The interaction of CXCR7 with CXCL11 further complicates
this chemokinergic system since CXCL11 also binds CXCR3, to
induce either proliferative or growth inhibitory signals, depending
on the CXCR3 variant (A or B; Singh et al., 2013). More-
over, besides CXCL11, CXCR3 is also bound by CXCL9 and
CXCL10 to promote tumor growth, metastasis, angiogenesis
and immune cell inﬁltration into tumors. GBM expression of
CXCR3 was conﬁrmed in human and murine GBM cell lines
and its activation promotes proliferation in vitro and experimen-
tal tumor progression in vivo (Liu et al., 2011). The biological
effects of the above described CK-receptor interactions is strictly
related to receptor afﬁnity, crosstalk of shared ligands, and
associated intracellular signaling in both normal and tumor
cells.
MULTIPLE ROLES OF CXCL12/CXCR4-R7 NETWORK:
REGULATION OF EARLY DEVELOPMENT OF THE CNS
CKs are pivotal regulators of cell migration, adhesion, and prolif-
eration not only during inﬂammation and immune surveillance
but also during CNS development. In particular, beside inﬂam-
matory or homeostatic leukocyte migration, CXCL12 retains a
primordial role, highly conserved through the evolution, in the
regulation of embryonic and adult stem cell directional migra-
tion. The ﬁrst evidence of the function of CXCL12 in neural
development was suggested by the lethal phenotype of CXCR4-
and CXCL12-knockout mice (Ma et al., 1998; Zou et al., 1998),
both exhibiting abnormal neuronal migration in the cerebellum,
dentate gyrus and dorsal root ganglia, in addition to defec-
tive lympho-myelopoiesis, and imperfect vasculature and heart
development. During cerebellar development CXCR4-positive
granule cell precursors are retained in the external granule
layer through their interaction with CXCL12 expressed in the
overlying pial meninges, ensuring sufﬁcient cell proliferation
and allowing the migration to the internal granule layer only
FIGURE 1 | Schematic diagram of proposed CXCR4–CXCR7 crosstalk
affecting major signaling pathways related to cell survival, proliferation,
and migration. CXCL12 binds to CXCR4 and CXCR7, which can form
homodimers or heterodimers. CXCR4–CXCR7 heterodimerization induces a
conformational change of CXCR4/G-proteins and blocks signaling.
CXCL12–CXCR4 interaction activated by CXCL12 triggers GPCR signaling
through PI3K/Akt, PLC/IP3, and ERK1/2 pathways, and mobilization of Ca2+
from endoplasmic reticulum via inhibition of adenyl cyclase mediated cAMP
production, thus regulating cell survival, proliferation, and chemotaxis.
Beta-arrestin pathway can be activated through GRK to internalize CXCR4.
When CXCR7 binds CXCL12, activation of the β-arrestin may lead to
scavenging of CXCL12. In glioblastoma CXCL12/CXCR7 also controls cell
survival through ERK1/2. AC, adenylyl cyclase; PLC, phospholipase C; PIP2;
phosphatidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5 trisphosphate; PI3K,
phosphoinositide-3 kinase; ERK1/2, extracellular regulated kinase 1/2; GRK,
GPCR kinase
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when the cerebellar cortex is ready to receive them. Altered
CXCL12/CXCR4 interaction causes a premature migration of
granule precursors and disorganized layer formation (Stumm
et al., 2003; Huang et al., 2014). CXCL12 anchors cerebellar gran-
ule precursors and favors their proliferation synergistically with
Sonic hedgehog (Shh). The CXCL12/CXCR4 axis also controls
the tangential migration of post-mitotic neurons (Tiveron et al.,
2006).
Thus, CXCL12/CXCR4 signaling regulates the development of
many structures in the central and peripheral nervous system,
including cerebellum, cortex, hippocampus and dorsal root and
sympathetic ganglia, controlling migration and positioning of
cerebellar granule cells, Cajal–Retzius cells, cortical interneurons,
and hindbrain pontine neurons (Li and Ransohoff, 2009; Zhu
et al., 2009; Zhu and Murakami, 2012). CXCL12/CXCR4 regula-
tionof stemcell functioning continues also in adults, inneurogenic
niches of brain and bonemarrow. Hematopoietic progenitors cells
(HPCs) are retained in bone marrow through a CXCR4/CXCL12
interaction that regulates also HPCs homing to this niche after
transplantation (Kaplan et al., 2007) survival and proliferation.
Interestingly, a similarmechanism has been demonstrated in adult
neural progenitor cells (NPCs) or neural stem cells (NSCs; Li and
Ransohoff, 2009).
First detected in the 1960s (Altman, 1962), two main areas
have been identiﬁed in adult mammalian brain where NSCs are
localized: the subventricular zone (SVZ) along the lateral walls of
the lateral ventricles, and the subgranular zone (SGZ) in the den-
tate gyrus of hippocampus. NSCs have the potential to self-renew,
proliferate, and differentiate into neurons, astrocytes, and oligo-
dendrocytes (Laywell et al., 2007), also in response to ischemic or
hypoxic insults (Yang and Levison, 2006; Laywell et al., 2007; Miles
and Kernie, 2008; Jin-qiao et al., 2009).
In postnatal brain, CXCR4 expression continues in NPCs in
SVZ of lateral ventricle and SGZ of dentate gyrus, the adult
brain neurogenic areas, while CXCL12 is expressed in ependy-
mal and endothelial cells adjacent to the proliferating areas.
CXCL12 triggers the homing of SVZ NSCs from the ependy-
mal niche to the vascular niche that is abrogated by CXCR4
knockdown. Notably, it has been suggested that the migration of
responsive cells to the vascular niche, or non-migration of rest-
ing cells in the ependymal niche, is regulated by the levels of
CXCL12 in the microenvironment (Miller and Gauthier-Fisher,
2009).
Thus, both in adult and embryonic brain, one of the main
physiological roles of the CXCL12/CXCR4 axis is the posi-
tioning of NPCs near blood vessels or meninges that provide
important source of factors for proliferation and differentia-
tion. Generally, CXCR7 has a more limited and less charac-
terized pattern of expression than CXCR4, and it is primar-
ily involved in vascular and cardiac development, rather than
hematopoiesis, as observed in vivo in CXCR7 knockout mice
that die at birth from severe heart and vascular defects (Sierro
et al., 2007). However, CXCR7 is also expressed during mouse
embryogenesis in the neural tube and brain concomitantly with
neural crest development and vascularization. (Schonemeier
et al., 2008b). During rat brain development, CXCR7 expres-
sion starts at E11.5, increases between E15 and E18 in the
marginal zone/layer I, and decreases postnatally. In the cerebral
cortex, CXCR7 is expressed in GABAergic neuron progenitors,
Cajal–Retzus cells, and neural precursors (Schonemeier et al.,
2008a).
The molecular function of CXCR7 within the brain has been
investigated by studies in zebraﬁsh that provided the ﬁrst and
strong evidence that CXCR7 acts as scavenger receptor, mediating
CXCL12 internalization and providing directional cell migra-
tion of primordial germ cells to the gonads and the formation
of the posterior lateral line. CXCR4 is expressed by migrating
cells and CXCR7 acts by sequestrating CXCL12 from non-target
areas, allowing the correct cell migration (Dambly-Chaudiere
et al., 2007). In the absence of CXCR7, migrating cells still
respond to CXCL12, but their movement ends in undesirable
sites because of a speciﬁc accumulation that prevents the forma-
tion of a CXCL12 gradient required for a directional migration.
(Boldajipour et al., 2008; Cubedo et al., 2009). In mammals, the
scavenger function of CXCR7 has been established in mouse
heart valve, as well as umbilical vein endothelial cells (Naumann
et al., 2010) and it was shown to be responsible of interneuron
migration. Accordingly, CXCR4 and CXCR7 are co-expressed
in migrating interneurons but they have a different subcellular
localization: CXCR4 in the plasma membrane and CXCR7 in
intracellular recycling endosomes (Wang et al., 2011; Sanchez-
Alcaniz et al., 2011). CXCR7 is frequently expressed, in the
absence of CXCR4, in forebrain in postnatally generated olfac-
tory interneuron precursors, further demonstrating that CXCR7
is an independent, direct mediator of CXCL12 signaling (Tiveron
et al., 2010).
The relevance of CXCL12 and CXCR4/R7, in CNS functions
and brain development is even more important considering the
consequences of the cancer stem cell hypothesis (Singh et al.,
2003, 2004a), based on the concept that tumors derive from cells
endowed with stem or stem-like features in which alterations of
the self-renewal mechanisms are induced. Therefore, understand-
ing the CK-dependent mechanisms associated with the stemness
in normal neural progenitors might help to clarify their activity in
cancer development.
ROLE OF CXCL12–CXCR4/R7 IN GLIOBLASTOMA
CXCL12–CXCR4/R7 system plays a central role in tumor devel-
opment and tumor cell proliferation, mainly acting via an
autocrine/paracrine mechanism, and contributes to the dissem-
ination and invasiveness of several human cancers, including
pancreatic, colon, ovarian, prostate, breast, and renal carcino-
mas, lymphoma, melanoma, neuroblastoma and GBM (Zlotnik,
2006; Barbieri et al., 2010; Lippitz, 2013; Singh et al., 2013).
Moreover, less malignant or benign tumors (i.e., pituitary ade-
nomas, meningiomas, etc.) seem to be regulated by the activity of
this chemokinergic axis (Bajetto et al., 2007; Barbieri et al., 2008;
Wurth et al., 2011).
Additionally, CXCR4 expression in tumor cells was associated
with metastasis of many human malignancies (Muller et al., 2001;
Ben-Baruch,2008; Zlotnik, 2008; Ferrari et al., 2012) favoring their
migration and homing toward CXCL12 expressing organs (lung,
liver, brain, lymph nodes, bone marrow; Teicher and Fricker,
2010).
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The signiﬁcance of the expression and function of the
CXCL12/CXCR4 axis in brain tumors has been intensely investi-
gated in adult and children GBM, astrocytoma, medulloblastoma,
oligodendroglioma, and oligodendroastrocytoma (Domanska
et al., 2011). In GBM, CXCR4 and CXCL12 are overexpressed in
tumor tissue when compared with normal adjacent parenchyma,
and their expression level is correlated with tumor grade and poor
prognosis (Salmaggi et al., 2005a; Bian et al., 2007). Immunohis-
tochemical studies showed that in GBM CXCR4 and CXCL12
expression does not co-localize with tumor proliferating cells
(identiﬁed by MIB-1 expressing cells) but they are both mainly
localized in hypoxic regions, characterized by necrosis (Rempel
et al., 2000; Salmaggi et al., 2005b; Zagzag et al., 2008). In these
perinecrotic areas (“pseudopalisading”necrosis), characterized by
high cellularity (Rempel et al., 2000; Bajetto et al., 2006; Rong
et al., 2006) due to the powerful invasion of glioma cells (Sci-
ume et al., 2010), CXCR4 and CXCL12 co-localize in the same
tumor cells (Bajetto et al., 2006). Pseudopalisade areas are pecu-
liar pathologic structures of GBM resulting from a sequence
of vascular occlusion and hypoxia (Brat and Van Meir, 2004)
leading to migration and accumulation of GBM cells around
central necrotic areas and microvascular hyperplasia induced
by hypoxic pseudopalisading cells (Jin et al., 2006). Hypoxia
promotes GBM angiogenesis, not only via hypoxia-inducible
factor-1α (HIF-1α) that directly induces the transcription of
VEGF and cytokines (i.e., TNF-α), and stimulates CXCL12
expression, but also up-regulates CXCR4 expression in pseu-
dopalisades. Thus, CXCL12 drives angiogenesis either directly
or in a paracrine manner, supporting tumor growth and GBM
cell migration far from hypoxic pseudopalisades, allowing for
both necrotic area formation and peripheral invasiveness of
GBM.
On the other hand, CXCR4 and CXCL12 expression frequently
occurs in GBM proliferating vascular endothelium, but not in
endothelial cells from astrocytomas in which proliferation of
microvessels is less abundant (Bajetto et al., 2006).
Interestingly, the mechanism of dissemination of glioma cells
within the brain, differently from other cancers, does not occur
through lymphatic and hematogeneous spread. GBM cells invade
the adjacent brain parenchyma with a morphological pattern
known as “Scherer’s structures” that include normal brain struc-
tures (white matter, blood vessels, and parenchyma) where
CXCL12 is highly expressed. GBM cells, organized around neu-
ron and blood vessels in subpial regions and in white matter
express high levels of CXCR4: VEGF-dependent CXCL12 up-
regulation in neuronal and endothelial cells induces the migration
of CXCR4-positive GBM cells, representing the molecular mech-
anisms of Scherer’s structure formation (Ehtesham et al., 2006;
Zagzag et al., 2008; Munson et al., 2013). CXCL12 exerts also
pro-angiogenic activity, recruiting CXCR4-positive, circulating
bone marrow-derived cells (Petit et al., 2007) and promoting
tumor vasculature recovery after irradiation, as a consequence of
treatment-induced hypoxia and HIF-1α activation, which results
in increased CXCL12 expression (Jin et al., 2006; Kioi et al.,
2010).
The ability of CXCL12 to guide GBM cell migration has been
widely supported by in vitro experiments (Rubin et al., 2003;
Bajetto et al., 2006) and, although the molecular mechanisms
involved are not deﬁnitively identiﬁed, the effect of CXCL12 results
from a functional cooperation with EGFR and PDGFR, over-
expressed in GBM cells (Woerner et al., 2005; Sciaccaluga et al.,
2013).
The tumor microenvironment, consisting of constitutive
non-cancerous cells (ﬁbroblasts, endothelial cells, and immune
cells), as well as connective tissue and extracellular matrix,
contributes to GBM (and other solid tumors) development,
proliferation, invasiveness and angiogenesis (Domanska et al.,
2013). CXCL12/CXCR4 axis acts on the tumor microenviron-
ment through the modulation of the expression and secre-
tion of other CKs (i.e., CCL2, CXCL8) and, concomitantly,
CXCR4 expression could be inﬂuenced by cytokines (TNFα,
IFNγ, IL4-6-10) produced by cells in the microenvironment.
These interactions represent an indirect mechanism mediating
CXCL12/CXCR4-dependent promotion of survival, proliferation
andmigration of tumor cells (Zhou et al., 2002; Burger and Kipps,
2006).
Hypoxia enhances CXCL12 secretion in cancer-associated
ﬁbroblasts which in turn feeds tumor development either by
direct stimulation of tumor cells expressing CXCR4 (paracrine
effect) or recruiting endothelial cells for angiogenesis (endocrine
effect; Burger and Kipps, 2006). Stromal ﬁbroblasts support the
growth of neoplastic cells through elevated secretion of CXCL12
(Orimo et al., 2005), and integrins induce expression of CXCR4
and growth-factor receptors sustaining a pro-survival loop for
tumor cells.
The interaction of GBM cells with the microenvironment that
protects cancer cells from the chemo- and radio-therapy stress,
becomes even more relevant in the context of CXCL12/CXCR4
up-regulation observed after treatment with anticancer drugs, and
particularly after anti-VEGF antibodies (Shaked et al., 2008; Kioi
et al., 2010; Keunen et al., 2011).
Several studies investigated the signal transduction of the
CXCL12/CXCR4 axis in normal glial cells or in cell lines
derived from human GBMs, being the expression of ligand
and receptor almost always reported. CXCR4 and CXCL12
expression was described in primary cultures of rat type I
astrocytes, cortical neurons and cerebellar granule cells and
treatment with CXCL12 induced proliferation of normal astro-
cytes through the activation of ERK1/2 and PI-3K pathways
(Bajetto et al., 1999a,b, 2001b). In human GBM cell lines (U87-
MG, DBTRG-05 and A172), CXCL12 that is released in the
extracellular medium, supports cell growth, likely through an
autocrine/paracrine mechanism by the activation of intracel-
lular ERK1/2 and Akt pathways (Barbero et al., 2002, 2003).
However, differently from normal astrocytes, GBM cell lines
show constitutive Akt activation, further increased by CXCL12,
and ERK1/2 and Akt are independently involved in cell prolif-
eration. Conversely, the glioma onco-suppressive gene LRRC4
inhibits CXCL12/CXCR4-induced cell proliferation, chemotaxis
and invasiveness reducing ERK1/2 and Akt signaling (Wu et al.,
2008).
In vivo studies, in which GBM cells are intracerebrally
implanted, showed that CXCL12/CXCR4 binding activates matrix
metalloproteinases (MMPs) that contribute to the inﬁltrative
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behavior of GBM cells within the brain parenchyma (Zhang et al.,
2005).
While CXCL12/CXCR4 activation within both cancer cells and
local stroma clearly contributes to GBM cell proliferation, spread-
ing, and survival to therapy, more recent studies demonstrated
that CXCR7 is an alternative, or additional, regulator of GBM
growth. CXCR7 is up-regulated in all pathological conditions in
which CXCL12 activity is enhanced, including neoplastic diseases,
and contributes to tumor growth, adhesion, survival, angiogenesis,
and invasion of breast, lung and prostate carcinomas (Miao et al.,
2007;Wang et al., 2008) and promotes tumor development inmice
(Burns et al., 2006). CXCR7 is highly expressed in tumor endothe-
lial, microglial, and GBM cells (Hattermann et al., 2010). CXCR7
controls tumor diffusion through CXCL12 gradients and it is fre-
quently detected in GBM-associated vasculature (Liu et al., 2010).
The increase of CXCR7 expression in microvascular endothe-
lial cells during hypoxia (Schutyser et al., 2007; Monnier et al.,
2012) favors CXCL12-induced glioma cell migration (Esencay
et al., 2013) facilitating the binding of CXCL12 to endothelial cells
(Burns et al., 2006; Liu et al., 2010; Dai et al., 2011) and the acti-
vation of CXCL12-mediated cell crossing through endothelium
(Mazzinghi et al., 2008; Zabel et al., 2009; Dai et al., 2011).
CXCL12, CXCR4–CXCR7 ACTIVITY IN HUMAN
GLIOBLASTOMA STEM-LIKE CELLS
In recent years, the CSC theory has gained more experimental
validation in addition to the reﬁned theoretical deﬁnition. In par-
ticular, GBM is the tumor histotype that more precisely matches
CSC criteria, in terms of heterogeneity and hierarchical orga-
nization of cells, identiﬁcation of stem cell features in tumor
cell subpopulations and, importantly, as far as pharmacological
responses. Thus, considering the signiﬁcant role of CXCL12–
CXCR4/R7 axis in normal stem cell biology, it is evident that this
chemokinergic system could play a relevant role in GBM CSCs.
Moreover, according to genotypic and phenotypic evidence of a
more close reproduction in vitro of the in vivo tumor characteris-
tics of cultures enriched inCSCs, as comparedwith established cell
lines (Lee et al., 2006), recent studies addressed the role of CXCL12
and its receptors in this GBM cell subpopulation (Figure 2).
GLIOBLASTOMA CANCER STEM CELLS
Glioblastoma is a complex, heterogeneous tissue characterized
by the coexistence of several different cell populations with a
hierarchical organization. Among them, a relatively small popu-
lation exhibits stem-like features, including the capacity to persist
in a constant number through asymmetric mitotic cell division
(self-renewal capacity), thus representing a drug-resistant cell
reservoir to generate differentiated cells (multilineage differenti-
ation potential), that in GBM are represented by differentiated
progeny expressing either neuronal or glial markers. After the
identiﬁcation of distinctive stem cell markers, these cells were
named cancer stem cells (CSCs). Importantly, besides showing
NSC properties, CSCs are tumorigenic, phenocopying the original
tumor when xenotransplanted in animal models. For this rea-
son, they are also called tumor-initiating cells (TICs), in order to
highlight their tumorigenic potential (Florio and Barbieri, 2012).
CSCs have been detected in different hematological and solid
tumors (Bonnet and Dick, 1997) and the ﬁrst evidence sup-
porting the presence of CSCs in GBM was reported in 2003
(Singh et al., 2003; Singh et al., 2004b). Several groups have sub-
sequently described the isolation and characterization of GBM
CSCs (Hemmati et al., 2003; Bao et al., 2006a; Liu et al., 2006;
Bajetto et al., 2013; Griffero et al., 2009). Initially, the pheno-
typic characterization of GBMCSCs was based on the recognition
of distinctive NSC markers, such as nestin, Sox2, Nanog, Oct4,
BMI1, musashi-1, but later on, components of pathways active
in brain development were found to be expressed in GBM CSCs,
including Notch (Wang et al., 2010a), Wnt (Jin et al., 2011), bone
morphogenetic protein (BMP; Piccirillo et al., 2006) and TGF-β
(Ikushima et al., 2009). The ﬁve-transmembrane domain glyco-
protein CD133 (prominin-1), initially reported as one of the
most reliable markers to identify GBM CSCs (Beier et al., 2007),
although conﬂicting reports were subsequently published and not
labeling all CSC subpopulations, is still considered a key compo-
nent of CSCs (Grosse-Gehling et al., 2013) acting as a regulator of
cell survival inducing PI3K-Akt activation, via a direct interaction
with p85 (Wei et al., 2013).
Conceivably, the plastic phenotype recently proposed for CSCs,
rather than unique cellular marker(s), is the most valid hypothe-
sis, also taking into account GBM cell heterogeneity and the high
degree of plasticity that favors its aggressive behavior (Florio and
Barbieri, 2012; Tang, 2012; Ruiz-Ontanon et al., 2013;Wurth et al.,
2014).
The origin of GBMCSCs is still unclear and controversial. CSCs
were proposed to derive from normal NSCs after the accumula-
tion of oncogenic mutations and/or following events mediated by
the microenvironment (Calabrese et al., 2007; Hjelmeland et al.,
2011). More recently, it was suggested that differentiated neurons
or astrocytes can be dedifferentiated and transformed, acquir-
ing CSC-like features to originate histologically different GBMs
(Friedmann-Morvinski et al., 2012).
Niches are the speciﬁc sites where normal stem cells reside and
in adult tissues constitute a spatially distinct microenvironment,
which contains stromal cells, blood vessels and high concentra-
tions of extracellular matrix proteins and growth factors. The
interaction between stem cells and speciﬁc niches is critical for
the maintenance of their functional properties, and, in particu-
lar, for the balance between self-renewal and differentiation that
regulates cell number and tissue homeostasis (Ramasamy et al.,
2013).
Like NSCs, GBM CSCs require speciﬁc niches in which a
permissive environment, ensuring the correct combination of
supporting cells (endothelial cells, reactive astrocytes, pericytes,
tumor-associated macrophages) and extrinsic factors, is essential
for their maintenance and regulation.
There are relevant similarities between NSC and CSC niche:
Vasculature
Blood vessels are an integral component of both neural and can-
cer stem cell niches. Endothelial cells (EC) modulate NSCs not
only by providing oxygen and nutrients, but also through regu-
lation of their capacity to self-renew, proliferate and differentiate
(Shen et al., 2004; Charles and Holland, 2010). A comparable and
intricate relationship occurs in the niche where CSCs are closely
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FIGURE 2 | CXCL12/CXCR4–CXCR7 system in the GBM CSC niche. GBM
CSC niche is a discrete microenvironment within the tumor mass. It is
composed of a heterogeneous cell population that generally includes blood
vessels, tumor cells, CSCs, extracellular matrix components, and a gradient
of soluble factors. CXCL12 secretion by endothelial cells, tumor cells, and
CSCs generates an autocrine and paracrine action which contributes to
self-renewal, survival and migration of CSCs themselves, triggering Akt and
MAP-kinase(s) intracellular signaling.
connected to ECs establishing a paracrine modulation between
these two cell types, largely mediated by the secretion of VEGF
and CXCL12 (Calabrese et al., 2007; Yao et al., 2013). GBM CSCs
not only release growth factors that induce proliferation of ECs
(Bao et al., 2006b) but also may be themselves a direct source
of angiogenesis by trans-differentiation into endothelial-like cells.
On the other hand, ECs maintain CSCs in undifferentiated state,
promote their tumorigenicity (Calabrese et al., 2007) and, via the
interaction CXCL12–CXCR4, maintain GBM CSCs localized in
the perivascular niche (Cheng et al., 2013).
Molecular signaling pathways
Developmental pathways (Notch, Wnt, Shh), and recep-
tors activated by ﬁbroblast growth factor (FGF), epidermal
growth factor (EGF), transforming growth factor (TGF)- β,
and CKs, primarily CXCL12, identiﬁed within the niche to
maintain NSCs during development and in adult brain, are
also involved in CSC survival (Gatti et al., 2013; Penuelas
et al., 2009). The interaction between these signal transduction
pathways results in self-renewal, sustained proliferation, and
increased survival, invasiveness and drug resistance of CSCs
(Mimeault et al., 2007).
CXCL12/CXCR4-R7 AXIS IN GBM CSC REGULATION
As previously detailed, CXCL12 modulates tumor cell prolifera-
tion, angiogenesis andmetastasis, acting as an autocrine/paracrine
growth factor (Barbero et al., 2003; Barbieri et al., 2008; Pattarozzi
et al., 2008), representing a promising target for the treatment
of neoplasia. The concept of CSCs and their identiﬁcation in
several tumors highlights possible new roles for the CXCL12–
CXCR4/R7 axis in tumor biology. CXCR4 (over)expression has
been detected in CSCs derived from various of cancer his-
totypes, including pancreatic (Hermann et al., 2007), colon
(Zhang et al., 2012), lung (Jung et al., 2013), breast (Dubrovska
et al., 2012b) prostate (Dubrovska et al., 2012a), renal (Gassen-
maier et al., 2013), and GBM (Singh et al., 2004b). More-
over, the recent demonstration that CXCR7 can also serve
as an active receptor for CXCL12 (Odemis et al., 2012) has
increased the interest for this chemokinergic system inCSC-related
research.
Preclinical studies addressing the role of CXCL12 inGBMCSCs
are listed in Table 1 (generated from PubMed, using “CXCL12–
CXCR4–CXCR7-GBM-CSCs” as keywords).
Criteria used to identify and maintain CSC cultures differ
among the various studies, mainly because of the absence of
absolute and uniform biomarkers and, different methods of CSC
isolation and in vitro culture enrichment have been reported,
making study comparisons difﬁcult. Although putative GBM
stem-like cells have been isolated as a subpopulation within
established cell lines, the isolation of tumor cell subpopula-
tions from human post-surgical explants, grown as non-adherent
neurospheres in serum-freemedium enriched with growth factors
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(Folkins et al., 2009), is currently considered the most reliable
source of GBM CSCs (Table 1). Long-term passaging of cells in
media containing high percentages of serum irreversibly modi-
ﬁes both the phenotype and genotype of the cells as compared
to those present in the original tumor, favoring the selection
of mutated cells more ﬁt to in vitro growth (Lee et al., 2006;
Wakimoto et al., 2012). Moreover, early passage GBM CSCs
grown under serum free conditions better recapitulate the in
vivo invasive characteristics of the parental tumor when grown as
intracranial xenografts, thus making them a more suitable model
system.
The selection of tumor cell subpopulations on the basis of the
expressionof speciﬁcbiomarkers common tobothNSCs andGBM
CSCs (in particular CD133 and nestin), could be performed as an
additional step. Culture conditions deﬁned for the propagation of
NSCs (serum-free medium containing EGF and bFGF) are effec-
tive to sustain GBM CSC growth in vitro, allowing cells to grow
as ﬂoating spheroids (neurospheres) that retain the stem cell phe-
notype. Noteworthy, neurosphere formation in limiting dilution
experiments is one of the main tools used to assess in vitro CSC
self-renewal (Carra et al., 2013). Finally, CSC isolation has to be
further veriﬁed by in vitro/in vivo analysis of functional proper-
ties, such as multilineage differentiation and, most importantly,
tumorigenicity in animal models.
The CXCL12–CXCR4 axis was reported as a main regula-
tor of GBM CSC biological features: self-renewal, prolifera-
tion, migration, angiogenesis, and chemo-and radio-resistance.
Overexpression of CXCR4 was observed in GBM CSCs, which
increased proliferation in response to exogenous CXCL12 (Eht-
esham et al., 2009). However, this CK is also released by
CSCs, suggesting an autocrine/paracrine signaling mechanism
(Salmaggi et al., 2006; Gatti et al., 2013). CXCR4 activation in
GBM CSCs, in combination with VEGF and HGF signaling
pathways under hypoxia, is a key factor in determining NSC
tropism toward gliomas (Zhao et al., 2008). Further corrob-
oration of these ﬁndings came from studies showing higher
CXCR4 expression in GBM CSC cultures than in the differen-
tiated tumor cells obtained from the same culture (Ehtesham
et al., 2009). These reports paved the way for further studies
that revealed high heterogeneity in CXCR4 expression amongst
CSC cultures derived from individual human GBMs (Liu et al.,
2013). This observation was supported and highlighted in a
recent study showing, in ﬁve different CSC cultures, that the
distinctive properties of original GBM are retained in vitro,
including CXCR4 expression and CXCL12 secretion, but were
highly variably among cultures, with a general inverse relation-
ship between receptor expression and ligand secretion levels (Gatti
et al., 2013).
In vitro, GBM CSC proliferation was induced either by
treatment with exogenous CXCL12 (Liu et al., 2013) or by
the receptor activation induced by CXCL12 secreted by CSCs
in an autocrine fashion (Uemae et al., 2014). This effect was
mainly mediated by CXCR4, since it was reversed in the pres-
ence of the CXCR4 antagonist AMD3100 (Schulte et al., 2011;
Gatti et al., 2013). On the other hand, it was observed that
the autocrine effects of CXCL12 promote GBM CSC survival
to a higher extent than proliferation: CXCR4 blockade by
AMD3100 reduces CSC survival proportionally to the amount
of spontaneously released of CXCL12 (Gatti et al., 2013).
The ability of AMD3100 to impair colony formation induced
by both exogenous and secreted CXCL12 in GBM CD133-
positive cells further conﬁrms the autocrine growth-stimulation
effect of this CK in this subset of GBM cells (Ping et al.,
2011).
The role of CXCL12/CXCR7 axis inGBMCSCbiologywas only
recently investigated and, even if a deﬁnitive establishment of its
role was not provided, strong evidence supports its involvement
in GBM CSC maintenance and tumorigenicity. Pharmacological
inhibition of CXCR7 post irradiation caused tumor regression,
reduced tumor recurrence, and substantially prolonged survival
in a rodent model of GBM, likely interfering with CSCs (Wal-
ters et al., 2014). Heterogeneous cell surface expression of CXCR4
and CXCR7, despite similar levels of corresponding mRNAs, was
also observed in primary GBM cell cultures. Analysis of cultures
enriched in CSCs determined increased percentage of CXCR4-
and CXCR7-expressing cells suggesting that both receptors might
regulate stem phenotype. Heterogeneous functional responses to
CXCL12 are evident, with different roles in promoting in vitro cell
growth, migration, spherogenesis, and tube formation in individ-
ual cultures (Liu et al., 2013). However, CXCR4+, CXCR7+, and
CXCR4+/CXCR7+ cell subpopulations present in cell cultures are
all tumorigenic (Lee et al., 2013; Liu et al., 2013).
Conversely, other studies reported that GBM CSCs do not
express, or express at a low level, CXCR7 (Hattermann et al.,
2010; Gatti et al., 2013). Moreover, upon GBM CSC differentia-
tion, CXCR4 levels diminish while CXCR7 increases, suggesting a
prevalent role forCXCR7 in differentiatedGBMcells (Hattermann
et al., 2010).
The role of CXCL12–CXCR4 axis in GBM CSCs was corrob-
orated by in vivo studies. In particular, knocking down CXCR4
using RNAi or inhibiting CXCR4 function by AMD3100 in CSCs,
impairs proliferation in vivo, effectively reducing tumor growth in
two different xenograft models (Ping et al., 2011; Lee et al., 2013);
similarly shRNA CXCL12 knock-down in CSCs inhibited tumor
growth in vivo (Uemae et al., 2014).
SELF-RENEWAL
Besides proliferation and survival, CXCL12/CXCR4 axis plays a
signiﬁcant role in maintaining CSC self-renewal. Self-renewal in
vitro can be evaluated through sphere formation and clonogenic-
ity assays. These tests were performed in two different models of
GBMCSCs (Gatti et al., 2013; Lee et al., 2013) showing that exoge-
nous CXCL12 promoted sphere formation, and that either the
pharmacological blockade of CXCR4 by AMD3100 (Gatti et al.,
2013) or silencing the receptor (Lee et al., 2013) suppressed CSC
sphere-forming ability after serial in vitro passages. The role of
CXCL12 in CSC sustained self-renewal was also supported by the
observation that disrupting CXCR4 signaling reduces the expres-
sion of genes associated with self-renewal activity (i.e., Oct4 and
Nanog; Lee et al., 2013). Similarly, CXCR7 inhibition by CCX771
powerfully affects CSC self-renewal (Walters et al., 2014). Taken
together, these data suggest that maintenance of stemness of
the CSC subpopulation represents a relevant function related to
CXCL12 activity.
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MIGRATION
CXCL12 stimulated in vitro migration of CSCs in a dose-
dependent manner and co-administration of AMD3100 inhibited
peak chemotactic responses. Conversely, the same treatment
resulted in minor effects in continuous glioma cell lines, and only
in the presence of extremely high concentrations of AMD3100
caused a statistically signiﬁcant inhibition of migration (Schulte
et al., 2011). However, individual CSC cultures displayed heteroge-
neous responses to CXCL12 in cell migration experiments in vitro.
In particular, CXCL12 induced AMD3100-sensitive cell migration
only in a subset of CSC cultures tested (Liu et al., 2013).
ANGIOGENESIS
CSCs are also responsible for the development of GBM microvas-
culature. Tumor microvessels were demonstrated to have a
neoplastic origin, and CSCs have been suggested to transdif-
ferentiate into functional ECs (Rodriguez et al., 2012). It was
demonstrated that GBM CSCs contribute to the microvascula-
ture formation by differentiating into ECs in vitro and in vivo,
and that GBM mouse xenografts contain human-derived ECs
(Ricci-Vitiani et al., 2010; Wang et al., 2010b; Soda et al., 2011).
More recently, vascular pericytes localized near ECs, have been
suggested as the actual tumor-derived cells in neovessels, and,
by lineage tracing in vivo, GBM CSCs have been proposed to
be the source of pericytes rather than ECs (Cheng et al., 2013).
CXCL12/CXCR4 axis, at least in part, contributes to GBMpericyte
formation inducingmigration of CXCR4-expressing CSCs toward
the perivascular niche, where ECs secrete CXCL12 (Ehtesham
et al., 2009; Folkins et al., 2009) and TGF-β drives differentiation
into mature pericytes (Cheng et al., 2013). Furthermore, CXCL12
stimulates VEGF secretion in CXCR4-expressing, CD133+ CSCs
from surgical specimens of human GBM and cell lines, pro-
moting tumor angiogenesis via PI3K/AKT signaling (Ping et al.,
2011). Discordant ﬁndings have been reported usingmurineGBM
stem-like cells, in which endothelial-like differentiation was asso-
ciated with CXCL12 expression but CXCL12/CXCR4 blockade did
not affect either in vitro tube formation or in vivo angiogenesis.
Thus autocrine/paracrine CXCL12 regulates GBM murine stem
cell proliferation but probably not angiogenesis (Uemae et al.,
2014).
TARGETING CXCL12–CXCR4/CXCR7 AXIS IN CANCER:
RATIONALE
The notion that CXCR4/R7 expression in cancer is, in most
cases, a negative prognostic factor is well supported (Bian et al.,
2007; Maderna et al., 2007). CXCL12/CXCR4 axis is involved
in tumor development favoring adaptation, survival and pro-
liferation of cancer cells and CSCs in the tumor environment
(Scotton et al., 2002; Zhou et al., 2002; Marchesi et al., 2004)
and increasing dissemination of CXCR4-expressing tumor cells
in response to CXCL12 gradients (Zlotnik et al., 2011) as CXCL12
is markedly expressed in most common sites of metastasis (liver,
brain and bone). Moreover, the pro-angiogenic role of CXCR4/R7
and the ability of CXCL12 to up-regulate and synergize with
VEGF support the therapeutic relevance of the pharmacologi-
cal targeting of this pathway. In particular, CXCL12–CXCR4/R7
axis drives hypoxia-dependent angiogenesis and invasiveness of
GBM progenitor cells (Ehtesham et al., 2009). CXCR4 also sus-
tains non-pharmacological resistance of tumor cells, through its
effects on the stromal microenvironment that supplies growth-
and drug-resistance signals to tumor cells (Burger and Kipps,
2006).
Thus speciﬁc targeting of CK receptors or CXCL12 itself
in cancer management may provide a valuable tool to modu-
late autocrine/paracrine signaling networks between cancer cells,
CSCs and key stromal components (blood vessels, immune cells,
ﬁbroblasts), responsible for tumor cell survival, insufﬁcient drug
delivery and reduced efﬁcacy of conventional anticancer drugs.
CXCR4/R7-based therapeutics might open up the concept of
microenvironment targeted therapy as a new pharmacological
strategy, to be used in combination with cytotoxic drugs. Indeed,
GBM growth and recurrence relies on CSCs that are responsible
for tumor vessel formation and bidirectionally interact with tumor
ECs via secreted factors, including CXCL12, to preserve stemness
and promote self-renewal (Stupp et al., 2005; Calabrese et al., 2007;
Gatti et al., 2013).
CXCR4 ANTAGONISTS IN CANCER MANAGEMENT
Most ﬁndings on the effects of CXCR4 antagonists in human
cancer were obtained in hematological malignancies, disrupting
the interactions between CXCR4-expressing leukemia cells and
CK secreted by the bone marrow microenvironment. Therefore,
results may not be directly translated to solid tumors, but ﬁnd-
ings could give interesting insights into the potential role of drugs
targeting CXCR4, as also shown in tumor animal models.
The discovery of CXCR4 as a co-receptor for T-cell tropic HIV-
1 led to the initial development of CXCR4 antagonists such as
T140 (Masuda et al., 1992), AMD3100 (De Clercq et al., 1992) and
ALX-4C (Doranz et al., 1997). Subsequently, the identiﬁcation of
non-HIV-related functions boosted new applications of CXCR4
inhibitors such as stem cellmobilization, inﬂammation and cancer
treatments.
CXCR4 antagonists can be classiﬁed as: (i) modiﬁed pep-
tides (T140 and its analogues, BKT140, POL6326, FC131); (ii)
small-molecules CXCR4 antagonists (AMD3100, AMD11070,
MSX-122, GSK812397); (iii) CXCL12 peptide analogs (CTCE-
9908 and CTCE-0214); or (iv) antibodies targeting CXCR4
(MDX-1338/BMS 93656, ALX-0651).
Peptide-based CXCR4 antagonists (TC14012, TZ14001 and
TN14003), derived from T140, demonstrated, in preclinical stud-
ies, ability to prevent tumor growth and metastasis in animal
models of breast, head, and neck carcinoma (Liang et al., 2004;
Yoon et al., 2007). In small cell lung cancer cells, TN14003 dis-
rupts CXCR4/CXCL12 interactions and blocks cell adhesion and
chemoresistance (Hartmann et al., 2005).
The development of molecules able to inhibit HIV-1/CXCR4
interaction, led to the identiﬁcation of AMD3100 (De Clercq,
2003), a bicyclam reversible antagonist, the most studied among
CXCL12/CXCR4 signaling inhibitors, shown to block CXCL12-
mediated calcium mobilization, chemotaxis, and GTP-binding.
AMD3100 efﬁcacy in hematopoietic stem cell mobilization was
tested in two successful randomized phase III clinical trials on
HIV-1 patients (DiPersio et al., 2009) and it was approved by FDA
and EMA, in association with G-CSF, for autologous bonemarrow
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transplantation in multiple myeloma (MM) and non-Hodgkin’s
lymphoma (NHL)(De Clercq, 2010).
CXCR4 blockade by AMD3100 decreases tumor growth in
preclinical GBM models. AMD4365, a novel derivative act-
ing as CXCR4 antagonist inhibits breast tumor formation and
reduces lung and liver metastasis (Ling et al., 2013) acting both
on tumor and immune cells present in the tumor microenvi-
ronment. Association of AMD3100 with bis-chloronitrosourea,
showed antitumor efﬁcacy in orthotopic models of GBM demon-
strating synergism between CXCR4 inhibition and conventional
cytotoxic therapies (Redjal et al., 2006). Currently a combina-
tion study with AMD3100 and bevacizumab for patients with
recurrent high-grade glioma is ongoing (https://clinicaltrials.gov)
with the hypothesis that blockade of CXCR4 will counteract
resistance mechanisms to VEGF inhibition. The anti-angiogenic
efﬁcacy of AMD3100 was also reported, resulting in a marked
reduction of tumor growth and invasiveness in orthotopic GBM-
xenotransplanted rats (Ali et al., 2013).
MSX-122, a small molecule identiﬁed as a “partial CXCR4
antagonist” (biased antagonist) that shows anti-metastatic activ-
ity in vivo through the unique property of blocking hom-
ing and recruitment of cells without mobilizing stem cells
(Liang et al., 2012). MSX-122 also inhibits the development of
ﬁbrotic process in mice, after radiation-induced lung injury
(Shu et al., 2013).
The orally bioavailable derivative AMD11070 powerfully
impairs CXCL12/CXCR4-mediated chemotaxis in vitro (Mosi
et al., 2012; O’Boyle et al., 2013), although phase I/II studies did
not warrant further development after safety and pharmacokinet-
ics assessment. BKT140, TG-0054, and POL6326 are currently in
clinical evaluation as stem cell mobilizers, for MM, leukemias and
lymphomas. The safety and efﬁcacy of BKT140 for mobilization
of human CD34+ cells in patients with MM has been recently
reported (Peled et al., 2014).
CTCE-9908, aCXCL12modiﬁedpeptide, beside hematopoietic
tumors, is the only CXCR4 antagonist approved analog by FDA
for solid tumors, and speciﬁcally for the treatment of osteogenic
sarcoma. CTCE-9908 inhibits human breast tumor cells growth in
mouse xenografts impairing the CXCR4–VEGF loop and lowering
tumorVEGF levels (Hassan et al., 2011) and affects breast, prostate
and esophageal cancer metastasization in murine models (Wong
and Korz, 2008; Richert et al., 2009). Phase I/II clinical trials of
this compound, in patients with hepatocellular carcinoma, are
currently under evaluation (Wong and Korz, 2008).
The emerging role of CXCR4 in tumor-stroma cross-talk has
a great therapeutic potential to deplete minimal residual disease
and CSCs: the disruption of CXCR4-mediated tumor cell adhe-
sion to stromal cells might sensitize residual cancer cells and stem
cells to standard cytotoxic drugs. In this respect, MDX-1338/BMS
93656,AMD3100 andBKT140 are currently under investigation in
phase I/II clinical studies for MM and chronic lymphoid leukemia
(CLL).
The development of antibodies against CK receptors has
promising therapeutic efﬁcacy, as reported in preclinical and
clinical studies. Pharmacological approaches using antibodies
exploit a dual mechanism: direct, by selective functional inhi-
bition of the target receptor and, indirect, by potentiation
of host immune response through the recruitment of cyto-
toxic monocytes/macrophages (i.e., antibody-dependent cell-
mediated cytotoxicity) or by binding complement factors (i.e.,
complement-dependent toxicity). Several CK-directed (CCL2,
CCL5, and CXCL10) antibodies have been generated and tested
in phase I/II clinical trials (Klarenbeek et al., 2012) in both
cancer and inﬂammatory diseases. 30D8, a humanized anti-
body against mouse/human CXCL12, inhibits tumor growth
and/or metastasis and improve arthritis in experimental in
vitro and in vivo models (Zhong et al., 2013). However, the
majority of antibodies that successfully entered clinical trials,
targets CK receptors rather than ligands. This development
was boosted by the identiﬁcation of the crystal structure of
the receptors, particularly concerning the N-terminal extracel-
lular domain, the most accessible region for antibody bind-
ing.
A fully-human CXCR4-targeting moAb, MDX-1338/BMS-
93656, able to prevent CXCL12 binding, abolished intra-
cellular Ca2+ increase and chemotaxis induced by CXCL12
and it is under study to treat relapsed leukemia or,
in combination with lenalidomide/dexamethasone or borte-
zomib/dexamethasone, relapsed/refractory MM (Kuhne et al.,
2013).
A new class of antibody-derived therapeutics, based on
single-domain heavy-chain (VHH) antibody fragment, named
nanobodies, displays high stability, low toxicity and antigen-
binding capacity. The ﬁrst CK receptor targeted nanobody against
CXCR4 (Jahnichen et al., 2010), showed 100-fold higher afﬁn-
ity than AMD3100. CXCR4 nanobodies completely inhibit entry
of CXCR4-tropic HIV-1 strains in vitro and intravenous injec-
tion mobilizes stem cell in animal models, acting similarly to
AMD3100 (Jahnichen et al., 2010). Currently, a CXCR4-inhibiting
nanobody, ALX-0651, is in phase I trial (https://clinicaltrials.gov:
NCT01374503).
Recent insights in structural features of both CXCR4 and
CXCL12 and structure-activity relationships, improved chem-
ical modeling and structure-based development of candidate
molecules to be screened as CXCR4-antagonists (Wu et al., 2010).
A virtual screening of the National Cancer Institute’s Open
Chemical Repository Collection, using a homology model of
CXCR4, led to the identiﬁcation of a lead structure (Kim et al.,
2012). Furthermore, a new family of CXCR4 modulators, as
phianidine A, identiﬁed by screening a library of marine com-
pounds using a simple pharmacophoric model identiﬁed after
CXCR4 crystal structure, was recently reported (Vitale et al.,
2013).
CXCR7 ANTAGONISTS
In addition to CXCR4, CXCR7 represents a viable target for
anticancer and antimetastatic drugs. Inhibition of CXCR7 with
selective antagonists in mice engrafted with breast and lung can-
cer cell lines and experiments testing overexpression or silencing
of CXCR7 in tumor cells, collectively support the idea that CXCR7
promotes tumor growth (Miao et al., 2007).
CXCR7 antagonists are expected to act mainly by reducing
tumor cell extravasation and thus metastasis, and blocking tumor
angiogenesis, as demonstrated by CCX771, a synthetic CXCR7
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ligandmarkedlymore potent at inhibiting transendothelialmigra-
tion than AMD3100. It also stimulates β-arrestin recruitment to
CXCR7 in a lymphoblastic leukemia model (Zabel et al., 2009).
Moreover, exposure of CXCR4+CXCR7+ cancer cells to CXCL12
greatly enhances migration of human Burkitt’s lymphoma cells
through a human HUVEC endothelial cell monolayer as in vitro
model of transendothelialmigration (Zabel et al., 2011) suggesting
the potential efﬁcacy of CXCR7 antagonists in blocking CXCL12-
mediated metastatic spread of CXCR4+CXCR7+ tumor cells, in
vivo.
CXCR7 is also an attractive therapeutic target for hematopoietic
stem cell (HSC) mobilization-inducing agents since its expression
might be necessary to direct HSCs to the niches sustaining their
capacity ofmigration. AlthoughCXCR7 regulationof BMSCniche
has not been completely deﬁned, it should represent a relevant goal
for research since the possible inclusion of CXCR7 antagonists in
the current formulation of HSC mobilizers (granulocyte-colony-
stimulating factor, G-CSF, plus AMD3100) might reduce the
percentage of patients in which that mobilization protocol fails
(To et al., 2011).
In order to fully elucidate the complex pharmacology and
potential therapeutic utility of CXCR7 receptor antagonists,
CXCR7 structural models would be highly useful. However, these
detailed structures are currently not available. At present, a lim-
ited number of CXCR7 ligands have been reported (Kalatskaya
et al., 2009; Gravel et al., 2010; Wijtmans et al., 2012), there-
fore the application of GPCR homology modeling and virtual
screening, previously used in CXCR4 studies, for novel CXCR7
ligand identiﬁcation represents a promising tool (Yoshikawa
et al., 2013). AMD3100 and the peptidomimetic CXCR4 antag-
onist TC14012 have also been reported to act as partial CXCR7
agonists (Kalatskaya et al., 2009; Gravel et al., 2010). Several
pharmacological studies with small-molecule CXCR7 antago-
nists endowed with reasonable afﬁnities have been reported,
but none disclosed a structure for the antagonists (Burns et al.,
2006; Zabel et al., 2009; Hattermann et al., 2010; Rajagopal et al.,
2010; Cruz-Orengo et al., 2011). A recent paper describes the
ﬁrst reported combined synthetic, modeling and pharmacolog-
ical effort on small molecules targeting CXCR7 (Wijtmans et al.,
2012).
DUAL TARGETING OF CXCR4-R7 OR CXCL12 BLOCKADE
Since CXCR4 and CXCR7 are both involved in cancer malignancy,
and in particular in GBM angiogenesis, molecules able to interact
and block either CXCL12 itself or both receptors simultaneously
could represent an improved pharmacological approach (Duda
et al., 2011; Singh et al., 2013).
However, as far as dual receptor binding the current available
data are rather complex. Some CXCR4 or CXCR7 antagonists
were reported to bind also the other receptor although not
always acting as antagonist, but partial agonist activity was
reported. This is also the case for the prototype CXCR4 antago-
nist AMD3100 that may act as CXCR7 partial agonist (Kalatskaya
et al., 2009). Moreover, CXCR7 agonists selectively activating
β-arestin were shown to down-regulate CXCR4 (Uto-Konomi
et al., 2013). This differential modulatory effect on the recep-
tors might induce complex biological responses according to the
cell analyzed. As far as GBM it was reported that CSCs mainly
express CXCR4 while CXCR7 is mainly located in differentiated
cells and endothelia (Hattermann et al., 2010; Gatti et al., 2013).
In other models the receptors are co-expressed, acting also as
heterodimers. Thus, the potential synergism induced by ligands
with dual speciﬁcity has to be evaluated in the speciﬁc cell con-
text and in relation to the agonist/antagonist properties of the
molecule.
A more deﬁned picture is obtainable blocking the activity of
both CXCR4 and CXCR7 interfering with their ligand. Indeed,
synthetic compounds from the family of chalcones, able to bind to
CXCL12 with high afﬁnity to prevent its binding to the recep-
tors, have been reported to inhibit inﬂammatory responses in
eosinophils (Hachet-Haas et al., 2008).
Moreover, NOX-A12, an RNA oligonucleotide that binds and
neutralizes CXCL12 with high afﬁnity (Liang et al., 2007), is
currently in clinical trial for leukemia and MM, displaying anti-
neoplastic activity and stem cell-mobilization from bone marrow.
NOX–A12 interferes with CLL cell motility and BMSC-mediated
drug resistance, sensitizing CLL cells towards bendamustine and
ﬂudarabine, in BMSC co-cultures. Noteworthy, NOX-A12 has
been recently reported to be effective in inhibiting or delaying
recurrences following irradiation in an in vivo GBM model (Liu
et al., 2014).
CONCLUSION
In recent years, molecularly targeted drugs have joined con-
ventional chemo- and radio-therapies for the management of
several cancers, and have become the ﬁrst-line treatments for
tumors lacking efﬁcacious therapeutic options, such as the
approval of bevacizumab for recurrent GBM. Beneﬁts of tar-
geted therapy in terms of overall survival are modest, however
in GBM,whose median survival is approximately 15months, even
an improvement of progression-free survival could be encour-
aging. In this context, the blockade of CXCR4/R7 signaling
represents an alternative or additional target for neo-adjuvant
treatments. However, a better understanding of the biology of
the CK receptors and ligands in CSCs, GBM tissue and stroma,
is needed to clarify their role in tumorigenesis and deﬁne the
actual best therapeutic target among stromal cells, CSC and
differentiated cancer cells or their whole cross-talk. In addi-
tion, since CXCR4 and CXCR7 are involved in angiogenesis,
targeting this chemokinergic system could improve the poor efﬁ-
cacy of inhibitors of angiogenesis in several cancers including
GBM.
Conceivably, the combination of CXCR4 and CXCR7 antago-
nists could represent powerful tool to reduce tumor cell invasion
and metastasis. Moreover, the role of CXCL12 pathway in tumor
resistance, acting both directly, to promote cancer cell and CSC
survival and angiogenesis, and indirectly, to recruit stromal cells
that through paracrine activity induce recurrence and metastasis,
is crucial for cancer therapy.
However, development of preclinical and translational research
targeting microenvironment in hematopoietic and solid malig-
nancies should be paralleled by solution of its limitations as the
actual beneﬁt of combination with cytotoxic agents, duration
(length) of responses and potential development of mechanisms
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of resistance. Moreover, each cancer type might require a differ-
ent CXCR4 antagonist, exploiting pharmacological features such
as oral availability and pharmacokinetics, and the prevalent ability
tomobilize hematopoietic cells or to inhibit metastasis or invasion
of cancer cells.
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